Global health focus Rabin Martin operates at the intersection of health outcomes, access, and equity, offering strategy to execution across multiple markets. This positions them to upsell expanded global health programs, health system strengthening, and market-entry support for medicines and vaccines in US, Europe, and LMICs.

Deep sector experience With decades of experience in commercial strategy, health equity, and therapeutic areas from cancer to rare diseases and maternal/child health, they are well-suited to sell end-to-end solutions including stakeholder engagement, policy navigation, and partnerships that unlock new payer or channel opportunities.

Strong partner network Their past work with UN entities, pharma players like J&J and Takeda, and major foundations creates credible footholds for co-delivery, joint ventures, or alliance-based projects, enabling co-bid opportunities and larger multi-stakeholder programs.

Proven execution track They claim to move from strategy to implementation with measurement and evaluation, suggesting a compelling value proposition for clients seeking not just plans but measurable health and market access outcomes, which can be upsold into broader program expansion.

Financial and scale signals Revenue range and prior acquisition by Omnicom indicate stability and potential cross-sell within large network agencies, and their project experience managing over $2 billion in health programming signals capacity for sizeable engagements and longer-term contracts.